Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.

Locke FL, Go WY, Neelapu SS.

JAMA Oncol. 2019 Nov 7:1-10. doi: 10.1001/jamaoncol.2019.3869. [Epub ahead of print]

PMID:
31697310
2.

Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma.

Strati P, Ahmed MAA, Fowler N, Nastoupil LJ, Samaniego F, Fayad LE, Hagemeister FB, Romaguera JE, Rodriguez A, Wang M, Westin JR, Cheah C, Noorani M, Feng L, Davis RE, Neelapu SS.

Haematologica. 2019 Oct 10. pii: haematol.2019.230649. doi: 10.3324/haematol.2019.230649. [Epub ahead of print]

3.

Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy.

Abu-Sbeih H, Tang T, Ali FS, Luo W, Neelapu SS, Westin JR, Okhuysen PC, Foo WC, Curry JL, Richards DM, Ge PS, Wang Y.

Am J Clin Oncol. 2019 Oct;42(10):789-796. doi: 10.1097/COC.0000000000000596.

PMID:
31478934
4.

Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.

Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, Byrne M, Jacoby E, Lazaryan A, Jacobson CA, Ansell SM, Awan FT, Burns L, Bachanova V, Bollard CM, Carpenter PA, DiPersio JF, Hamadani M, Heslop HE, Hill JA, Komanduri KV, Kovitz CA, Lazarus HM, Serrette JM, Mohty M, Miklos D, Nagler A, Pavletic SZ, Savani BN, Schuster SJ, Kharfan-Dabaja MA, Perales MA, Lin Y.

Biol Blood Marrow Transplant. 2019 Aug 22. pii: S1083-8791(19)30529-4. doi: 10.1016/j.bbmt.2019.08.015. [Epub ahead of print] Review.

PMID:
31446199
5.

A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis.

Manasanch EE, Han G, Mathur R, Qing Y, Zhang Z, Lee H, Weber DM, Amini B, Berkova Z, Eterovic K, Zhang S, Zhang J, Song X, Mao X, Morgan M, Feng L, Baladandayuthapani V, Futreal A, Wang L, Neelapu SS, Orlowski RZ.

Blood Adv. 2019 Aug 13;3(15):2400-2408. doi: 10.1182/bloodadvances.2019000300. Erratum in: Blood Adv. 2019 Sep 24;3(18):2712.

6.

Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function.

Gunther JR, Park C, Dabaja BS, Milgrom SA, Cruz Chamorro RJ, Medeiros LJ, Khoury JD, Garg N, Amini B, Steiner R, Nair R, Strati P, Westin JR, Ju Lee H, Fowler N, Nastoupil L, Neelapu SS, Pinnix CC.

Leuk Lymphoma. 2019 Aug 2:1-5. doi: 10.1080/10428194.2019.1644333. [Epub ahead of print] No abstract available.

PMID:
31373240
7.

Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma.

Andraos TY, Ayoub Z, Nastoupil LJ, Milgrom SA, Pinnix CC, Ng SP, Gunther JR, Fowler NH, Neelapu SS, Samaniego F, Fayad LE, Dabaja BS.

Leuk Lymphoma. 2019 Jun 24:1-8. doi: 10.1080/10428194.2019.1627535. [Epub ahead of print]

PMID:
31234671
8.

Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma.

Jain N, Hartert K, Tadros S, Fiskus W, Havranek O, Ma MCJ, Bouska A, Heavican T, Kumar D, Deng Q, Moore D, Pak C, Liu CL, Gentles AJ, Hartmann E, Kridel R, Smedby KE, Juliusson G, Rosenquist R, Gascoyne RD, Rosenwald A, Giancotti F, Neelapu SS, Westin J, Vose JM, Lunning MA, Greiner T, Rodig S, Iqbal J, Alizadeh AA, Davis RE, Bhalla K, Green MR.

Sci Transl Med. 2019 Jun 19;11(497). pii: eaav5599. doi: 10.1126/scitranslmed.aav5599.

9.

Managing the toxicities of CAR T-cell therapy.

Neelapu SS.

Hematol Oncol. 2019 Jun;37 Suppl 1:48-52. doi: 10.1002/hon.2595. Review.

PMID:
31187535
10.

Clinical Features of Rituximab-associated Gastrointestinal Toxicities.

Mallepally N, Abu-Sbeih H, Ahmed O, Chen E, Shafi MA, Neelapu SS, Wang Y.

Am J Clin Oncol. 2019 Jun;42(6):539-545. doi: 10.1097/COC.0000000000000553.

PMID:
31136371
11.

Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection.

Strati P, Nastoupil LJ, Fayad LE, Samaniego F, Adkins S, Neelapu SS.

Blood. 2019 Jun 27;133(26):2800-2802. doi: 10.1182/blood.2019000888. Epub 2019 May 17. No abstract available.

PMID:
31101626
12.

Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare.

Kim ST, Bittar M, Kim HJ, Neelapu SS, Zurita AJ, Nurieva R, Suarez-Almazor ME.

J Immunother Cancer. 2019 May 14;7(1):126. doi: 10.1186/s40425-019-0597-x.

13.

Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma.

Pinnix CC, Milgrom SA, Cheah CY, Gunther JR, Ludmir EB, Wogan CF, Nastoupil LJ, Neelapu SS, Westin J, Lee HJ, Iyer SP, Steiner RE, Fayad LE, Fowler NH, Wang ML, Samaniego F, Rodriguez MA, Rich AE, Medeiros LJ, Dabaja BS.

Blood Adv. 2019 May 14;3(9):1356-1367. doi: 10.1182/bloodadvances.2018029140.

14.

CXCR5+CD8+ T cells are a distinct functional subset with an antitumor activity.

Chu F, Li HS, Liu X, Cao J, Ma W, Ma Y, Weng J, Zhu Z, Cheng X, Wang Z, Liu J, Jiang ZY, Luong AU, Peng W, Wang J, Balakrishnan K, Yee C, Dong C, Davis RE, Watowich SS, Neelapu SS.

Leukemia. 2019 Nov;33(11):2640-2653. doi: 10.1038/s41375-019-0464-2. Epub 2019 Apr 25.

15.

CAR-T efficacy: is conditioning the key?

Neelapu SS.

Blood. 2019 Apr 25;133(17):1799-1800. doi: 10.1182/blood-2019-03-900928. No abstract available.

PMID:
31023743
16.

Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy.

Ayoub Z, Andraos T, Milgrom SA, Pinnix CC, Dabaja BS, Ng SP, Gunther JR, Khoury JD, Fowler NH, Neelapu SS, Samaniego F, Fayad LE, Nastoupil LJ.

Leuk Lymphoma. 2019 Oct;60(10):2432-2440. doi: 10.1080/10428194.2019.1597081. Epub 2019 Apr 3.

PMID:
30942648
17.

Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial.

Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, Hagemeister FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Forbes SG, Feng L, Neelapu SS, Fowler NH.

Br J Haematol. 2019 Jun;185(5):874-882. doi: 10.1111/bjh.15843. Epub 2019 Mar 28.

18.

Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.

Strati P, Neelapu SS.

Curr Oncol Rep. 2019 Mar 27;21(5):38. doi: 10.1007/s11912-019-0789-z. Review.

PMID:
30919158
19.

Reply.

Lee DW, Mead E, Santomasso BD, Turtle CJ, Grupp SA, Neelapu SS.

Biol Blood Marrow Transplant. 2019 Jun;25(6):e211-e212. doi: 10.1016/j.bbmt.2019.03.019. Epub 2019 Mar 23. No abstract available.

PMID:
30910604
20.

Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma.

Khashab T, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Vega F, Kwak LW, Samaniego F.

Br J Haematol. 2019 May;185(4):670-678. doi: 10.1111/bjh.15814. Epub 2019 Feb 28.

PMID:
30820940
21.

Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma.

Strati P, Lee ST, Teegavarupu P, Karri A, Anireddy S, Hagemeister FB, Romaguera J, Fayad LE, Rodriguez MA, Samaniego F, Fowler N, Westin J, Wang M, Lee HJ, Pinnix C, Gunther JR, Dabaja B, Feng L, Davis RE, Neelapu SS.

Am J Hematol. 2019 Jun;94(6):E150-E153. doi: 10.1002/ajh.25447. Epub 2019 Mar 6. No abstract available.

PMID:
30785215
22.

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS.

Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25. Review.

23.

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS.

Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.

24.

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.

Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR.

J Immunother Cancer. 2018 Dec 4;6(1):137. doi: 10.1186/s40425-018-0460-5. Review.

25.

Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy.

Sheu T, Milgrom SA, Andraos TY, Gunther JR, Chi L, Nastoupil L, Fowler N, Oki Y, Fanale MA, Fayad LE, Hagemeister F, Neelapu SS, Medeiros LJ, Hosing C, Nieto Y, Ahmed S, Alousi AM, Dabaja B, Pinnix CC.

Adv Radiat Oncol. 2018 Jul 12;3(4):639-646. doi: 10.1016/j.adro.2018.07.001. eCollection 2018 Oct-Dec.

26.

The promise of CAR T-cell therapy in aggressive B-cell lymphoma.

Nair R, Neelapu SS.

Best Pract Res Clin Haematol. 2018 Sep;31(3):293-298. doi: 10.1016/j.beha.2018.07.011. Epub 2018 Aug 1. Review.

27.

Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy.

Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Taraseviciute A, Bollard CM, Tewari P, Duncan C, Traube C, McCall D, Steiner ME, Cheifetz IM, Lehmann LE, Mejia R, Slopis JM, Bajwa R, Kebriaei P, Martin PL, Moffet J, McArthur J, Petropoulos D, O'Hanlon Curry J, Featherston S, Foglesong J, Shoberu B, Gulbis A, Mireles ME, Hafemeister L, Nguyen C, Kapoor N, Rezvani K, Neelapu SS, Shpall EJ; Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network.

Nat Rev Clin Oncol. 2019 Jan;16(1):45-63. doi: 10.1038/s41571-018-0075-2. Review.

PMID:
30082906
28.

Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis.

Chihara D, Fowler NH, Oki Y, Fanale MA, Nastoupil LJ, Westin JR, Fayad LE, Neelapu SS, Cheah CY.

Oncotarget. 2018 Jun 22;9(48):28897-28902. doi: 10.18632/oncotarget.25622. eCollection 2018 Jun 22.

29.

CAR T-Cell Therapy in Large B-Cell Lymphoma.

Neelapu SS, Locke FL, Go WY.

N Engl J Med. 2018 Mar 15;378(11):1065. doi: 10.1056/NEJMc1800913. No abstract available.

PMID:
29539277
30.

The risk of central nervous system relapses in patients with peripheral T-cell lymphoma.

Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Oki Y.

PLoS One. 2018 Mar 14;13(3):e0191461. doi: 10.1371/journal.pone.0191461. eCollection 2018.

31.

Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol.

Thomas SK, Cha SC, Smith DL, Kim KH, Parshottam SR, Rao S, Popescu M, Lee VY, Neelapu SS, Kwak LW.

BMC Cancer. 2018 Feb 13;18(1):187. doi: 10.1186/s12885-018-4094-2.

32.

Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'.

Neelapu SS, Tummala S, Kebriaei P, Wierda W, Locke FL, Lin Y, Jain N, Daver N, Gulbis AM, Adkins S, Rezvani K, Hwu P, Shpall EJ.

Nat Rev Clin Oncol. 2018 Apr;15(4):218. doi: 10.1038/nrclinonc.2018.20. Epub 2018 Feb 13. No abstract available.

33.

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY.

N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.

34.

Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP.

Strati P, Fowler N, Pina-Oviedo S, Medeiros LJ, Overman MJ, Romaguera JE, Nastoupil L, Wang M, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad L.

Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e103-e108. doi: 10.1016/j.clml.2017.11.001. Epub 2017 Nov 14.

PMID:
29196178
35.

Novel BAFF-Receptor Antibody to Natively Folded Recombinant Protein Eliminates Drug-Resistant Human B-cell Malignancies In Vivo.

Qin H, Wei G, Sakamaki I, Dong Z, Cheng WA, Smith DL, Wen F, Sun H, Kim K, Cha S, Bover L, Neelapu SS, Kwak LW.

Clin Cancer Res. 2018 Mar 1;24(5):1114-1123. doi: 10.1158/1078-0432.CCR-17-1193. Epub 2017 Nov 27.

36.

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.

Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ.

Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. doi: 10.1038/nrclinonc.2017.148. Epub 2017 Sep 19. Review.

37.

Absence of Grail promotes CD8+ T cell anti-tumour activity.

Haymaker C, Yang Y, Wang J, Zou Q, Sahoo A, Alekseev A, Singh D, Ritthipichai K, Hailemichael Y, Hoang ON, Qin H, Schluns KS, Wang T, Overwijk WW, Sun SC, Bernatchez C, Kwak LW, Neelapu SS, Nurieva R.

Nat Commun. 2017 Aug 10;8(1):239. doi: 10.1038/s41467-017-00252-w.

38.

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.

Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek J, Go WY, Gisselbrecht C.

Blood. 2017 Oct 19;130(16):1800-1808. doi: 10.1182/blood-2017-03-769620. Epub 2017 Aug 3. Erratum in: Blood. 2018 Feb 1;131(5):587-588.

39.

Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma.

Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad LE, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler NH, Turturro F, Westin JR, Wang ML, McLaughlin P, Pinnix CC, Milgrom SA, Dabaja B, Horowitz SB, Younes A.

Blood. 2017 Jul 27;130(4):472-477. doi: 10.1182/blood-2017-02-766121. Epub 2017 May 18.

40.

Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma<sup/>.

Ho JC, Dabaja BS, Milgrom SA, Smith GL, Reddy JP, Mazloom A, Young KH, Deng L, Medeiros LJ, Dong W, Allen PK, Andraos TY, Fowler NH, Nastoupil LJ, Oki Y, Fayad LE, Turturro F, Neelapu SS, Westin J, Hagemeister FB, Rodriguez MA, Pinnix CC.

Leuk Lymphoma. 2017 Dec;58(12):2833-2844. doi: 10.1080/10428194.2017.1312381. Epub 2017 May 9.

41.

An interim analysis of the ZUMA-1 study of KTE-C19 in refractory, aggressive non-Hodgkin lymphoma.

Neelapu SS.

Clin Adv Hematol Oncol. 2017 Feb;15(2):117-120. Review. No abstract available.

PMID:
28398281
42.

High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.

Nastoupil LJ, McLaughlin P, Feng L, Neelapu SS, Samaniego F, Hagemeister FB, Ayala A, Romaguera JE, Goy AH, Neal E, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Fowler NH.

Br J Haematol. 2017 Apr;177(2):263-270. doi: 10.1111/bjh.14541. Epub 2017 Mar 24.

43.

Platelet activating factor-induced expression of p21 is correlated with histone acetylation.

Damiani E, Puebla-Osorio N, Lege BM, Liu J, Neelapu SS, Ullrich SE.

Sci Rep. 2017 Feb 3;7:41959. doi: 10.1038/srep41959.

44.

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.

Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, Jiang Y, Xue AX, Elias M, Aycock J, Wiezorek J, Go WY.

Mol Ther. 2017 Jan 4;25(1):285-295. doi: 10.1016/j.ymthe.2016.10.020. Epub 2017 Jan 4.

45.

IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay.

Weng J, Moriarty KE, Baio FE, Chu F, Kim SD, He J, Jie Z, Xie X, Ma W, Qian J, Zhang L, Yang J, Yi Q, Neelapu SS, Kwak LW.

Oncoimmunology. 2016 Oct 7;5(12):e1237327. doi: 10.1080/2162402X.2016.1237327. eCollection 2016.

46.

Chimeric Antigen Receptor T Cells in Hematologic Malignancies.

Shank BR, Do B, Sevin A, Chen SE, Neelapu SS, Horowitz SB.

Pharmacotherapy. 2017 Mar;37(3):334-345. doi: 10.1002/phar.1900. Epub 2017 Feb 22. Review.

PMID:
28079265
47.

3D microvascular model recapitulates the diffuse large B-cell lymphoma tumor microenvironment in vitro.

Mannino RG, Santiago-Miranda AN, Pradhan P, Qiu Y, Mejias JC, Neelapu SS, Roy K, Lam WA.

Lab Chip. 2017 Jan 31;17(3):407-414. doi: 10.1039/c6lc01204c.

48.

Targeting B-cell malignancies through human B-cell receptor specific CD4+ T cells.

Weng J, Baio FE, Moriarty KE, Torikai H, Wang H, Liu Z, Maiti SN, Gwak D, Popescu MS, Cha SC, Cooper LJ, Neelapu SS, Kwak LW.

Oncoimmunology. 2016 Sep 19;5(11):e1232220. doi: 10.1080/2162402X.2016.1232220. eCollection 2016.

49.

The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.

Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y.

Br J Haematol. 2017 Mar;176(5):750-758. doi: 10.1111/bjh.14477. Epub 2016 Dec 16.

50.

Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity.

Cheah CY, Nastoupil LJ, McLaughlin P, Fanale MA, Neelapu SS, Fayad LE, Hagemeister FB, Fowler NH.

Br J Haematol. 2016 Nov;175(3):531-533. doi: 10.1111/bjh.13863. Epub 2015 Dec 18. No abstract available.

PMID:
26683805

Supplemental Content

Loading ...
Support Center